Overview
- Eli Lilly’s market value topped roughly $1 trillion on Friday as shares rose about 1.6%, marking a first for the health care sector.
- GLP‑1 medicines Mounjaro and Zepbound drove more than $10 billion of the company’s $17.6 billion third‑quarter revenue, now representing over half of sales.
- Lilly plans to file for FDA approval of its oral GLP‑1 pill orforglipron by year‑end, with some analysts projecting potential U.S. launch in 2026 and peak annual sales near $40 billion.
- Analysts turned more bullish following the milestone, with Citi lifting its price target to $1,500, citing the obesity franchise’s momentum and pipeline depth.
- Lilly’s lead over Novo Nordisk widened as it captured roughly 58% of the GLP‑1 market and benefited from earlier rival supply constraints, while reported U.S. access deals could boost volume at lower prices.